<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>24256007</identifier>
<setSpec>0214-753X</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Monteverde, M</dc:author>
<dc:author>Rousseau, M</dc:author>
<dc:author>Schaiquevich, P</dc:author>
<dc:author>Imventarza, O</dc:author>
<dc:author>Dip, M</dc:author>
<dc:author>Cáceres Guido, P</dc:author>
<dc:author>Riva, N</dc:author>
<dc:author>Mato, G</dc:author>
<dc:description xml:lang="en">AIM To develop a pharmacovigilance program of calcineurin inhibitors used in pediatric renal and liver transplant patients at Hospital de Pediatría JP Garrahan, Argentina. METHODS Adverse drug reactions (ADRs) of pediatric patients with kidney and liver transplantation treated with calcineurin inhibitors (cyclosporine and tacrolimus) were evaluated by retrospective review of medical records of patients transplanted between 2010 and 2011. In addition, we carried out active pharmacovigilance since March, 2011. ADRs were reported to the National Health Authority. RESULTS A total of 59 patients, 28 kidney transplant and 31 liver tarnsplant patients were analyzed. In both transplants, 60 ADRs to cyclosporine were reported including (number of cases), hypertension (19) and nephrotoxicity (6). In addition, 46 ADRs to tacrolimus were registered as hypomagnesemia (25), hypertension (7) and nephrotoxicity (5). A total of 95% and 96% of the adverse events to cyclosporine and tacrolimus, respectively, were defined as probable or definitive. Lastly, 70% and 98% of the events to cyclosporine and tacrolimus respectively, have been moderately severe or severe. CONCLUSIONS This is the first study in Latin America that developed an intensive qualitative and quantitative analysis of the ADRs to calcineruin inhibitors in pediatric kidney and liver transplant patients. Spontaneous reporting should be motivated as well as monitoring ADRs should continue in the medium and long term for improving patient's quality of life.</dc:description>
<dc:type>English Abstract</dc:type>
<dc:language>es</dc:language>
<dc:date>2013 Nov-Dec </dc:date>
<dc:title xml:lang="es">Farmacovigilancia de inhibidores de calcineurina en trasplante renal y hep&amp;aacute;tico pedi&amp;aacute;trico.</dc:title>
<dc:description xml:lang="es">
             Objetivo: Desarrollar un programa de farmacovigilancia de pacientes pedi&amp;aacute;tricos trasplantados hep&amp;aacute;ticos y renales centrado en inmunosupresores calcineur&amp;iacute;nicos del Hospital de Pediatr&amp;iacute;a JP Garrahan de Argentina. M&amp;eacute;todos: Se evaluaron las reacciones adversas a medicamentos (RAM) de los pacientes pedi&amp;aacute;tricos trasplantados renales y hep&amp;aacute;ticos de nuestro hospital tratados con inhibidores de calcineurina (ciclosporina y tacrolimus) por revisi&amp;oacute;n retrospectiva de historias cl&amp;iacute;nicas de pacientes trasplantados en 2010-2011, y an&amp;aacute;lisis prospectivo por farmacovigilancia activa de trasplantados fuera de dicho per&amp;iacute;odo, cuyas complicaciones se hayan presentado en los ateneos semanales del Servicio de Trasplante desde marzo de 2011. Las RAM se notificaron a la autoridad sanitaria nacional. Resultados: Se analizaron un total de 59 pacientes, 28 trasplantados renales y 31 hep&amp;aacute;ticos. Se notificaron, en ambos trasplantes, 60 RAM a ciclosporina destac&amp;aacute;ndose (n&amp;uacute;mero de casos) hipertensi&amp;oacute;n arterial (19) y nefrotoxicidad (6). Asimismo, se registraron 46 RAM a tacrolimus, incluyendo hipomagnesemia (25), hipertensi&amp;oacute;n (7) y nefrotoxicidad (5). El 95% y 96% de los eventos adversos a ciclosporina y a tacrolimus, respectivamente, han sido agrupados como probables o definitivos. El 70% y 98% de los eventos adversos a ciclosporina y a tacrolimus respectivamente, han sido de severidad moderada o grave. Conclusiones: Este es el primer proyecto en Am&amp;eacute;rica Latina que propone y desarrolla el estudio cuali-cuantitativo intensivo de RAM a inhibidores de calcineurina en trasplante pedi&amp;aacute;trico renal y hep&amp;aacute;tico. Es necesario estimular la notificaci&amp;oacute;n espont&amp;aacute;nea as&amp;iacute; como continuar el seguimiento de RAM a mediano y largo plazo para mejorar la calidad de vida del paciente trasplantado. 
        </dc:description>
<dc:title xml:lang="en">[Pharmacovigilance of calcineurin inhibitor in peidatric kidney and liver transplantation].</dc:title>
<dc:publisher>Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria</dc:publisher>
</metadata>
</record>
</pubmed-document>
